ACP
RPTP

Acuta Capital Partners’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Acuta Capital Partners’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-174,708
Closed -$938K – 87
2016
Q2 		$938K Buy
+174,708
New +$896K 0.45% 46

Other funds holding RPTP

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Acuta Capital Partners's RPTP Position: Q3 2016 in Review

Acuta Capital Partners sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q3 2016, closing a stake of 174,708 shares — an estimated $938K sold.

Acuta Capital Partners first reported a position in RPTP in Q2 2016 and held it in 1 quarter. The position peaked at $938K in Q2 2016. 111 funds tracked by Wall St. Rank hold RPTP as of Q3 2016.

  • Acuta Capital Partners reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q3 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 174,708 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2016, an estimated $938K.
  • Acuta Capital Partners first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2016 and held it in 1 quarter.
  • Acuta Capital Partners's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $938K in Q2 2016.
  • 111 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2016.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.